APUS shows severe cash burn acceleration with operating cash flow deteriorating 51% to -$5.1M while R&D expenses nearly doubled, creating significant liquidity concerns for this early-stage pharmaceutical company.
The company's accumulated deficit ballooned from $7.5M to $9.2M in just one quarter, with quarterly net losses increasing 58% to $4.8M, indicating unsustainable burn rates. With cash declining 20% to $7.0M and current burn patterns, the company faces potential liquidity constraints within 3-4 quarters unless additional funding is secured.
APUS demonstrates classic early-stage biotech distress patterns with R&D expenses doubling to $1.3M driving operating losses to -$4.9M, while cash reserves declined 20% to $7.0M. The balance sheet contracted 12% as liabilities grew 35% and equity eroded 16%, reflecting unsustainable cash consumption. Combined with accelerating operating cash outflows of -$5.1M, the financial trajectory suggests imminent capital raising needs or potential going concern risks.
Capital expenditure jumped 168.6% — major investment cycle underway; assess returns on deployment.
R&D investment increased 95.1% — signals commitment to future product development, though near-term margin impact.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 58.1% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow fell 51% — earnings quality concerns; investigate working capital changes and non-cash items.
Liabilities grew 34.7% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 34.7% — significant near-term obligations; verify ability to meet short-term debt.
Cash decreased 20% — monitor burn rate and upcoming capital needs.
Equity decreased 16.2% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 12.3% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →